This guideline covers the care and support of adults receiving social care in their own homes, residential care and community settings. It aims to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care.
This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.
This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.
This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.
This guideline covers referral and assessment for intermediate care and how to deliver the service. Intermediate care is a multidisciplinary service that helps people to be as independent as possible. It provides support and rehabilitation to people at risk of hospital admission or who have been in hospital. It aims to ensure people transfer from hospital to the community in a timely way and to prevent unnecessary admissions to hospitals and residential care.
This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.
Evidence-based decisions on Endocuff Vision for assisting visualisation during colonoscopy
Evidence-based recommendations on Curos for preventing infections when using needleless connectors
Evidence-based recommendations on Thopaz+ for people who need chest drainage after a pulmonary resection or because of a collapsed lung
Evidence-based recommendations on Memokath-051 stent for treating ureteric obstruction
Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy (nerve damage) by detecting inadequate sweat production
Evidence-based recommendations on iFuse titanium implant joint fusion system for treating chronic sacroiliac (SI) joint pain (lower back pain)
Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain
Evidence-based recommendations on ENDURALIFE-powered cardiac resynchronisation therapy-defibrillator (CRT-D) devices for treating heart failure
Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography
Evidence-based recommendations on HumiGard for preventing inadvertent perioperative hypothermia in patients having abdominal surgery
Evidence-based recommendations on the Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms
Evidence-based recommendations on the Ambu aScope4 Broncho for use in unexpected difficult airways
Evidence-based recommendations on the moorLDI2-BI a laser doppler blood flow imager for burn wound assessment
Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds
Evidence-based recommendations on the Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters
Evidence-based recommendations on PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites
Evidence-based recommendations on the XprESS multi-sinus dilation system for treating chronic sinusitis after medical treatment has failed
Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery
Evidence-based recommendations on SecurAcath for securing percutaneous catheters (central venous catheters/CVCs)
Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions
Evidence-based recommendations on the Peristeen transanal irrigation system for people with bowel dysfunction
Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers
Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers
Evidence-based recommendations on the 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites
Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta
NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C (HCV) in adults
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery for adults with early breast cancer
NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence
NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis (MS) in adults
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults
NICE is unable to make a recommendation about the use in the NHS of bosutinib for untreated chronic myeloid leukaemia because no evidence submission was
NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive
NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the
NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from
Evidence-based recommendations on Holoclar for treating limbal stem cell deficiency in adults after eye burns
Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults
NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was
NICE was unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was
NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE is unable to make a recommendation about the use in the NHS of afatinib for advanced squamous non-small-cell lung cancer after platinum-based chemotherapy